Efficacy and Tolerance of Abacavir/Lamivudine Treatment in Patients With Systemic Lupus Erythematosus

NCT06356740 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

70

Enrollment

OTHER

Sponsor class

Conditions

Systemic Lupus Erythematosus

Interventions

BIOLOGICAL: Blood sample
DRUG: Treatment :Abacavir 600 mg/lamivudine 300 mg
OTHER: Lupus Impact Tracker questionnaire

Sponsor

Hospices Civils de Lyon